99 research outputs found
Surgical treatment in wrist instabilities
Department of Traumatology and Orthopedics, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova
Clinical Hospital of Orthopedics and TraumatologyIntroduction. Wrist joint instabilities are ligament injuries associated with subluxations,
luxations, fractures, nonunions or osteoarticular diseases of carpal bones. There are type of
surgery to resolve these problems.
Materials and methods. Our experience is based on the treatment of 129 patients with wrist
instabilities of different etiology aged between 17 and 68 years who underwent various selective
arthrodesis. The average duration of disease was 3 years and 2 months. Kienbock disease was
diagnosed in 41 patients, in various stages, pseudoarthrosis of the scaphoid complicated by
deforming osteoarthritis - in 71 cases, rotational subluxation of the scaphoid - in 9 cases,
trapezium-trapezoid-scaphoid osteoarthritis â in 4 patients and malunion of the distal radius
fracture â in 4 cases.
Results. Arthrodesis directed to obtain an ankylosis of the carpal bones by losing the amplitude
of movements, but allows to achieve a stable joint, without pain and to restore gripping power. In
71 patients with scaphoid pseudoarthrosis, complicated with deforming osteoarthritis, arthrodesis
of 4 carpal bones with scaphoidectomy in different variants was performed in 49 cases, total
wrist arthrodesis in 8 cases, scaphocapitate arthrodesis in 4 cases, removing the first row of
carpal bones in 3 cases, scaphoidectomy in 5 cases, radial-scaphoid arthrodesis â in 1 case, and 1
other in scapho-trapezium-trapezoid arthrodesis. In 41 patients with Kienbock disease, Graner
operation was performed in 16 cases, arthrodesis of 3 carpal bones in 10 cases, capitate-scaphoid
arthrodesis â in 8 cases, radial-semilunar â in 4 cases, radial-scaphoid arthrodesis â in 1 case,
removing the first row of carpal bones â in 2 cases. Arthrodesis of 3 carpal bones (scaphotrapezium-
trapezoid), was performed in 4 cases of deforming arthritis. Also triple scaphoid
arthrodesis was done successfully in 9 patients with rotational subluxation of the scaphoid. Total
wrist arthrodesis was performed in 4 cases of the intraarticular radial fracture malunion. Longterm
results were followed up in 46 patients: good (18), satisfactory (23). Unsatisfactory
outcomes were in 5 cases because of absence of the ankylosis and presence of the pain.
Conclusions. Selective wrist arthrodesis is indicated in deforming arthritis grade II or III of
diverse etiology, when outstanding amplitude movements are up to 50% of normal range.
Each case of selective wrist arthrodesis is chosen individually according to disease, the spreading
grade of deforming osteoarthritis and patient profession
Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model
The new chemokine Prokineticin 2 (PROK2) and its receptors (PKR1 and PKR2) have a role in inflammatory pain and
immunomodulation. Here we identified PROK2 as a critical mediator of neuropathic pain in the chronic constriction injury (CCI)
of the sciatic nerve in mice and demonstrated that blocking the prokineticin receptors with two PKR1-preferring antagonists (PC1
and PC7) reduces pain and nerve damage. PROK2 mRNA expression was upregulated in the injured nerve since day 3 post injury
(dpi) and in the ipsilateral DRG since 6 dpi. PROK2 protein overexpression was evident in Schwann Cells, infiltrating macrophages
and axons in the peripheral nerve and in the neuronal bodies and some satellite cells in the DRG. Therapeutic treatment of
neuropathic mice with the PKR-antagonist, PC1, impaired the PROK2 upregulation and signalling. This fact, besides alleviating
pain, brought down the burden of proinflammatory cytokines in the damaged nerve and prompted an anti-inflammatory repair
program. Such a treatment also reduced intraneural oedema and axon degeneration as demonstrated by the physiological skin
innervation and thickness conserved in CCI-PC1 mice. These findings suggest that PROK2 plays a crucial role in neuropathic pain
and might represent a novel target of treatment for this disease
Halogenated triazinediones behave as antagonists of PKR1: in vitro and in vivo pharmacological characterization
Different prokineticin receptor antagonists, based on the triazinedione scaffold, were synthesized by a new efficient method. Here we demonstrated that 5-benzyltriazinedionessubstituted in position para of the benzyl group with halogens provide compounds endowed with interesting selectivity for the Prokineticin receptor 1 (PKR1). BRET technology indicates that such substitutionresults in increased affinity for thePKR1.The affinity for PKR2, always in ïM range, was never significantly affected by the para-halogen-benzyl pharmacophores. The analog bearing a para-bromobenzyl pharmacophore (PC-25) displayed the highest affinity for PKR1 (~18 times higher than the reference PC-1 that bears apara-ethyl benzyl group) and the highest selectivity (~300 times). The other halogen substitutedanalogs (PC-7, PC-18 and PC-35), showed selectivity for PKR1 more than 100 times higher than for PKR2. Using transgenic mice lacking one of the two PKRs we demonstrated that all these compounds were able to abolish the Bv8-induced hyperalgesia in mice still expressing the PKR1 at doses lower than those necessary to abolish hyperalgesia in mice expressing only the PKR2. The dose ratio reflected the in- vitro evaluated receptor selectivity
Increasing incidence of HIVâ associated tuberculosis in Romanian injecting drug users
Background: A high prevalence of tuberculosis (TB) among HIVâpositive injecting drug users (IDUs) may fuel the TB epidemic in the general population of Romania. We determined the frequency and characteristics of TB in HIVâinfected IDUs referred to a national centre. / Methods: Prospective observational cohort study of all newlyâdiagnosed HIVâpositive IDUs admitted to Victor Babes Hospital, Bucharest, between January 2009 and December 2014. Socioâdemographics, clinical characteristics and outcomes of HIV/TB coâinfected IDUs were compared to HIVâpositive IDUs without TB. / Results: 170/598 (28.5%) HIVâinfected IDUs were diagnosed with TB. The prevalence increased from 12.5% in 2009 to 32.1% in 2014 (P < 0.001). HIV/TB coâinfected individuals had lower median CD4 cell counts 75 (vs. 450/mm3, P < 0.0001) and higher median HIV viral loads 5.6 log10 (vs. 4.9 log10, P < 0.0001) when presenting to healthcare services. 103/170 (60.6%) HIV/TB coâinfected IDUs were diagnosed with pulmonary TB. Resistant Mycobacterium tuberculosis strains were common, with 18/105 (17.1%) of patients having MultiâDrug Resistant (MDR) disease. Higher mortality rate was associated with TB coâinfection (P < 0.0001), extraâpulmonary TB (P = 0.0026) and extensively drug resistant TB (P = 0.024). / Conclusions: Tuberculosis (TB) is an increasing problem in HIVâinfected IDUs in Romania. Presentation is often with advanced HIV, significant TB drug resistance and consequent outcomes are poor
The impact of viral mutations on recognition by SARS-CoV-2 specific TÂ cells.
We identify amino acid variants within dominant SARS-CoV-2 TÂ cell epitopes by interrogating global sequence data. Several variants within nucleocapsid and ORF3a epitopes have arisen independently in multiple lineages and result in loss of recognition by epitope-specific TÂ cells assessed by IFN-Îł and cytotoxic killing assays. Complete loss of TÂ cell responsiveness was seen due to Q213K in the Aâ01:01-restricted CD8+ ORF3a epitope FTSDYYQLY207-215; due to P13L, P13S, and P13T in the Bâ27:05-restricted CD8+ nucleocapsid epitope QRNAPRITF9-17; and due to T362I and P365S in the Aâ03:01/Aâ11:01-restricted CD8+ nucleocapsid epitope KTFPPTEPK361-369. CD8+ TÂ cell lines unable to recognize variant epitopes have diverse TÂ cell receptor repertoires. These data demonstrate the potential for TÂ cell evasion and highlight the need for ongoing surveillance for variants capable of escaping TÂ cell as well as humoral immunity.This work is supported by the UK Medical Research Council (MRC); Chinese Academy of Medical Sciences(CAMS) Innovation Fund for Medical Sciences (CIFMS), China; National Institute for Health Research (NIHR)Oxford Biomedical Research Centre, and UK Researchand Innovation (UKRI)/NIHR through the UK Coro-navirus Immunology Consortium (UK-CIC). Sequencing of SARS-CoV-2 samples and collation of data wasundertaken by the COG-UK CONSORTIUM. COG-UK is supported by funding from the Medical ResearchCouncil (MRC) part of UK Research & Innovation (UKRI),the National Institute of Health Research (NIHR),and Genome Research Limited, operating as the Wellcome Sanger Institute. T.I.d.S. is supported by a Well-come Trust Intermediate Clinical Fellowship (110058/Z/15/Z). L.T. is supported by the Wellcome Trust(grant number 205228/Z/16/Z) and by theUniversity of Liverpool Centre for Excellence in Infectious DiseaseResearch (CEIDR). S.D. is funded by an NIHR GlobalResearch Professorship (NIHR300791). L.T. and S.C.M.are also supported by the U.S. Food and Drug Administration Medical Countermeasures Initiative contract75F40120C00085 and the National Institute for Health Research Health Protection Research Unit (HPRU) inEmerging and Zoonotic Infections (NIHR200907) at University of Liverpool inpartnership with Public HealthEngland (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford.L.T. is based at the University of Liverpool. M.D.P. is funded by the NIHR Sheffield Biomedical ResearchCentre (BRC â IS-BRC-1215-20017). ISARIC4C is supported by the MRC (grant no MC_PC_19059). J.C.K.is a Wellcome Investigator (WT204969/Z/16/Z) and supported by NIHR Oxford Biomedical Research Centreand CIFMS. The views expressed are those of the authors and not necessarily those of the NIHR or MRC
Recurrent SARS-CoV-2 mutations in immunodeficient patients
Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in immunodeficient patients are an important source of variation for the virus but are understudied. Many case studies have been published which describe one or a small number of long-term infected individuals but no study has combined these sequences into a cohesive dataset. This work aims to rectify this and study the genomics of this patient group through a combination of literature searches as well as identifying new case series directly from the COVID-19 Genomics UK (COG-UK) dataset. The spike gene receptor-binding domain and N-terminal domain (NTD) were identified as mutation hotspots. Numerous mutations associated with variants of concern were observed to emerge recurrently. Additionally a mutation in the envelope gene, T30I was determined to be the second most frequent recurrently occurring mutation arising in persistent infections. A high proportion of recurrent mutations in immunodeficient individuals are associated with ACE2 affinity, immune escape, or viral packaging optimisation.There is an apparent selective pressure for mutations that aid cellâcell transmission within the host or persistence which are often different from mutations that aid inter-host transmission, although the fact that multiple recurrent de novo mutations are considered defining for variants of concern strongly indicates that this potential source of novel variants should not be discounted. © The Author(s) 2022. Published by Oxford University Press
Spatial growth rate of emerging SARS-CoV-2 lineages in England, September 2020-December 2021
This paper uses a robust method of spatial epidemiological analysis to assess the spatial growth rate of multiple lineages of SARS-CoV-2 in the local authority areas of England, September 2020âDecember 2021. Using the genomic surveillance records of the COVID-19 Genomics UK (COG-UK) Consortium, the analysis identifies a substantial (7.6-fold) difference in the average rate of spatial growth of 37 sample lineages, from the slowest (Delta AY.4.3) to the fastest (Omicron BA.1). Spatial growth of the Omicron (B.1.1.529 and BA) variant was found to be 2.81Ă faster than the Delta (B.1.617.2 and AY) variant and 3.76Ă faster than the Alpha (B.1.1.7 and Q) variant. In addition to AY.4.2 (a designated variant under investigation, VUI-21OCT-01), three Delta sublineages (AY.43, AY.98 and AY.120) were found to display a statistically faster rate of spatial growth than the parent lineage and would seem to merit further investigation. We suggest that the monitoring of spatial growth rates is a potentially valuable adjunct to outbreak response procedures for emerging SARS-CoV-2 variants in a defined population
Genomic reconstruction of the SARS-CoV-2 epidemic in England.
The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus leads to new variants that warrant timely epidemiological characterization. Here we use the dense genomic surveillance data generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of subepidemics that peaked in early autumn 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. The Alpha variant grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed the Alpha variant and eliminated nearly all other lineages in early 2021. Yet a series of variants (most of which contained the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. However, by accounting for sustained introductions, we found that the transmissibility of these variants is unlikely to have exceeded the transmissibility of the Alpha variant. Finally, B.1.617.2/Delta was repeatedly introduced in England and grew rapidly in early summer 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on 26 June 2021
Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes
Summary Background The first epidemic wave of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Scotland resulted in high case numbers and mortality in care homes. In Lothian, over one-third of care homes reported an outbreak, while there was limited testing of hospital patients discharged to care homes. Aim To investigate patients discharged from hospitals as a source of SARS-CoV-2 introduction into care homes during the first epidemic wave. Methods A clinical review was performed for all patients discharges from hospitals to care homes from 1st March 2020 to 31st May 2020. Episodes were ruled out based on coronavirus disease 2019 (COVID-19) test history, clinical assessment at discharge, whole-genome sequencing (WGS) data and an infectious period of 14 days. Clinical samples were processed for WGS, and consensus genomes generated were used for analysis using Cluster Investigation and Virus Epidemiological Tool software. Patient timelines were obtained using electronic hospital records. Findings In total, 787 patients discharged from hospitals to care homes were identified. Of these, 776 (99%) were ruled out for subsequent introduction of SARS-CoV-2 into care homes. However, for 10 episodes, the results were inconclusive as there was low genomic diversity in consensus genomes or no sequencing data were available. Only one discharge episode had a genomic, time and location link to positive cases during hospital admission, leading to 10 positive cases in their care home. Conclusion The majority of patients discharged from hospitals were ruled out for introduction of SARS-CoV-2 into care homes, highlighting the importance of screening all new admissions when faced with a novel emerging virus and no available vaccine
- âŠ